Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat

Journal of Neurochemistry

Volumn 134, Issue 2, 2015, Pages 222-232

  Bhide, Nirmal ^b   Lindenbach, David ^a   Barnum, Christopher J ^a   George, Jessica A ^a   Surrena, Margaret A ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

dyskinesia; L DOPA; microdialysis; norepinephrine; Parkinson's disease; Propranolol

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; LEVODOPA METHYL ESTER; NORADRENALIN; PROPRANOLOL; QUINPIROLE; SEROTONIN; ANTIPARKINSON AGENT; LEVODOPA;

ADULT; AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EXTRACELLULAR SPACE; IN VIVO STUDY; LEVODOPA-INDUCED DYSKINESIA; MALE; MICRODIALYSIS; NONHUMAN; NORADRENALIN BRAIN LEVEL; PARKINSONISM; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; ANIMAL; DRUG EFFECTS; DYSKINESIA, DRUG-INDUCED; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT;

PARKINSONIA; RATTUS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MICRODIALYSIS; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84936756558     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13125     Document Type: Article

References (56)

1. Ahlskog J. E., and, Muenter M. D., (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448-458.
2. Arai A., Tomiyama M., Kannari K., Kimura T., Suzuki C., Watanabe M., Kawarabayashi T., Shen H., and, Shoji M., (2008) Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter. Synapse 62, 632-635.
3. Barnum C. J., Bhide N., Lindenbach D., Surrena M. A., Goldenberg A. A., Tignor S., Klioueva A., Walters H., and, Bishop C., (2012) Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats. Pharmacol. Biochem. Behav. 100, 607-615.
4. Bhide N., Lindenbach D., Surrena M. A., Goldenberg A. A., Bishop C., Berger S. P., and, Paquette M. A., (2013) The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat. Psychopharmacology 227, 533-544.
5. Bishop C., Krolewski D. M., Eskow K. L., Barnum C. J., Dupre K. B., Deak T., and, Walker P. D., (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J. Neurosci. Res. 87, 1645-1658.
6. Buck K., and, Ferger B., (2010) The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Synapse 64, 117-126.
7. Buck K., Voehringer P., and, Ferger B., (2010) The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J. Neurochem. 112, 444-452.
8. Carpentier A. F., Bonnet A. M., Vidailhet M., and, Agid Y., (1996) Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 46, 1548-1551.
9. Carta M., Carlsson T., Kirik D., and, Björklund A., (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833.
10. Cenci M. A., and, Lindgren H. S., (2007) Advances in understanding L-DOPA-induced dyskinesia. Curr. Opin. Neurobiol. 17, 665-671.
11. Cenci M. A., and, Lundblad M., (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 2007, 41, 9.25:9.25.1-9.25.23.
12. Cenci M. A., Lee C. S., and, Björklund A., (1998) (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694-2706.
13. Chang J. W., Wachtel S. R., Young D., and, Kang U. J., (1999) Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88, 617-628.
14. Chotibut T., Fields V., and, Salvatore M. F., (2014) Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals. Mol. Pharmacol. 86, 675-685.
15. Dekundy A., Lundblad M., Danysz W., and, Cenci M. A., (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 179, 76-89.
16. Delfino M. A., Stefano A. V., Ferrario J. E., Taravini I. R. E., Murer M. G., and, Gershanik O. S., (2004) Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behav. Brain Res. 152, 297-306.
17. Dupre K. B., Eskow K. L., Negron G., and, Bishop C., (2007) The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 1158, 135-143.
18. Dupre K. B., Ostock C. Y., Eskow Jaunarajs K. L., Button T., Savage L. M., Wolf W., and, Bishop C., (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp. Neurol. 229, 288-299.
19. Eskow K. L., Gupta V., Alam S., Park J. Y., and, Bishop C., (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 87, 306-314.
20. Eskow K. L., Dupre K. B., Barnum C. J., Dickinson S. O., Park J. Y., and, Bishop C., (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63, 610-620.
21. Fornal C. A., Marrosu F., Metzler C. W., Tada K., and, Jacobs B. L., (1994) (1994) Effects of the putative 5-hydroxytryptamine1A antagonists BMY 7378, NAN 190 and (-)-propranolol on serotonergic dorsal raphe unit activity in behaving cats. J. Pharmacol. Exp. Ther. 270, 1359-1366.
22. Fox S. H., (2013) Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs 73, 1405-1415.
23. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J. Q., Calne D. B., Ruth T. J., and, Stoessl A. J., (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127, 2747-2754.
24. Fulceri F., Biagioni F., Ferrucci M., Lazzeri G., Bartalucci A., Galli V., Ruggieri S., Paparelli A., and, Fornai F., (2007) Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res. 2007, 1135, 219-229.
25. Goetz C. G., Damier P., Hicking C., Laska E., Müller T., Olanow C. W., Rascol O., and, Russ H., (2007) Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord. 22, 179-186.
26. Goshima Y., Misu Y., Arai N., and, Misugi K., (1991) Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease. Jpn. J. Pharmacol. 55, 93-100.
27. Hara M., Fukui R., Hieda E., Kuroiwa M., Bateup H. S., Kano T., Greengard P., and, Nishi A., (2010) Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons. J. Neurochem. 113, 1046-1059.
28. Hornykiewicz O., (2006) The discovery of dopamine deficiency in the parkinsonian brain. J. Neural. Transm. 70, 9-15.
29. Kannari K., Kurahashi K., Tomiyama M., Maeda T., Arai A., Baba M., Suda T., and, Matsunaga M., (2002) Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54, 133-137.
30. Kilpatrick I. C., Jones M. W., and, Phillipson O. T., (1986) A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J. Neurochem. 46, 1865-1876.
31. Lane E. L., Cheetham S. C., and, Jenner P., (2006) Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp. Neurol. 197, 284-290.
32. Lewitt P. A., Hauser R. A., Lu M., Nicholas A. P., Weiner W., Coppard N., Leinonen M., and, Savola J.-M., (2012) Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79, 163-169.
33. Lindenbach D., Ostock C. Y., Eskow Jaunarajs K. L., Dupre K. B., Barnum C. J., Bhide N., and, Bishop C., (2011) Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. J. Pharmacol. Exp. Ther. 337, 755-765.
34. Lindgren H. S., Andersson D. R., Lagerkvist S., Nissbrandt H., and, Cenci M. A., (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 112, 1465-1476.
35. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and, Cenci M. A., (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15, 120-132.
36. Meitzen J., Luoma J. I., Stern C. M., and, Mermelstein P. G., (2011) β1-Adrenergic receptors activate two distinct signaling pathways in striatal neurons. J. Neurochem. 116, 984-995.
37. Miguelez C., Aristieta A., Cenci M. A., and, Ugedo L., (2011) The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study. PLoS ONE 6, e24679. doi: 10.1371/journal.pone.0024679.
38. Monville C., Torres E. M., and, Dunnett S. B., (2005) Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. 68, 16-23.
39. National Academies Press (2011) Guide for the Care and Use of Laboratory Animals, 8th Ed.
40. Olsson M., Nikkhah G., Bentlage C., and, Björklund A., (1995) Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15, 3863-3875.
41. Ostock C. Y., Lindenbach D. L., Goldenberg A. A., Kampton E., and, Bishop C., (2014) Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat. Behav. Brain Res. 270, 75-85.
42. Pavese N., Evans A. H., Tai Y. F., Hotton G., Brooks D. J., Lees A. J., and, Piccini P., (2006) Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67, 1612-1617.
43. Paxinos G., and, Watson C., (1998) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
44. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M. A., and, Calabresi P., (2003) (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6, 501-506.
45. Pollack A. E., and, Yates T. M., (1999) Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats. Neuroscience 94, 505-514.
46. Rainbow T. C., Parsons B., and, Wolfe B. B., (1984) Quantitative autoradiography of beta 1- and beta 2-adrenergic receptors in rat brain. Proc. Natl Acad. Sci. USA 81, 1585-1589.
47. Rascol O., Arnulf I., Peyro-Saint Paul. H., et al,. (2001) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 16, 708-713.
48. Reisine T. D., Chesselet M. F., Lubetzki C., Chéramy A., and, Glowinski J., (1982) A role for striatal beta-adrenergic receptors in the regulation of dopamine release. Brain Res. 241, 123-130.
49. Rommelfanger K. S., and, Weinshenker D., (2007) Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 74, 177-190.
50. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.-A., Hervé D., Greengard P., and, Fisone G., (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 27, 6995-7005.
51. Savola J.-M., Hill M., Engstrom M., Merivuori H., Wurster S., McGuire S. G., Fox S. H., Crossman A. R., and, Brotchie J. M., (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 18, 872-883.
52. Shin E., Rogers J. T., Devoto P., Bjorklund A., and, Carta M., (2014) Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Exp. Neurol. 257, 25-38.
53. Taylor J. L., Bishop C., and, Walker P. D., (2005) Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol. Biochem. Behav. 81, 887-893.
54. Waeber C., Rigo M., Chinaglia G., Probst A., and, Palacios J. M., (1991) Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease. Synapse 8, 270-280.
55. Wang Y., Wang H. S., Wang T., Huang C., and, Liu J., (2014) L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum. J. Neurosci. Res. 92, 1733-1745.
56. Winkler C., Kirik D., Björklund A., and, Cenci M. A., (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10, 165-186.